Mechanism of Action and Clinical Potential of Fingolimod for the Treatment of Stroke.
Fingolimod (FTY720) is an orally bio-available immunomodulatory drug currently approved by the FDA for the treatment of multiple sclerosis. Currently, there is a significant interest in the potential benefits of FTY720 on stroke outcomes. FTY720 and the sphingolipid signaling pathway it modulates has a ubiquitous presence in the central nervous system and both rodent models and pilot clinical trials seem to indicate that the drug may improve overall functional recovery in different stroke subtypes. Although the precise mechanisms behind these beneficial effects are yet unclear, there is evidence that FTY720 has a role in regulating cerebrovascular responses, blood-brain barrier permeability, and cell survival in the event of cerebrovascular insult. In this article, we critically review the data obtained from the latest laboratory findings and clinical trials involving both ischemic and hemorrhagic stroke, and attempt to form a cohesive picture of FTY720's mechanisms of action in stroke.
Department of Neurology and Rehabilitation, University of Illinois College of Medicine , Chicago, IL , USA.
Wentao
W
Li
Department of Pathology, University of Illinois College of Medicine , Chicago, IL , USA.
Haoliang
H
Xu
Department of Neurology and Rehabilitation, University of Illinois College of Medicine , Chicago, IL , USA.
Fernando D
FD
Testai
FTY720; fingolimod; hemorrhagic stroke; neuroprotection; sphingosine-1-phosphate; stroke; vascular endothelium